EDESA BIOTECH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 38.75K shares, a 73.12% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 0.00 shares 10-Q · filed 2026-02-13 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | 0.00 shares 10-K · filed 2025-12-12 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-13 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | |
| 2024-12-31 | 0.00 shares 10-Q · filed 2026-02-13 | |
| 2024-09-30 | 0.00 shares 10-K · filed 2025-12-12 | |
| 2023-09-30 | 0.00 shares 10-K · filed 2024-12-13 | |
| 2020-09-30 | 4.45K shares 10-Q · filed 2021-05-14 | |
| 2015-09-30 | -86.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14 | 38.75K shares 10-K · filed 2015-12-14 |
| 2015-06-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-10 | |
| 2015-03-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-11 | |
| 2014-12-31 | 125.00K shares 10-Q · filed 2015-02-09 | |
| 2014-08-31 | 144.17K shares 10-K · filed 2015-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |